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Abstract
Background: The vulnerability of newborn babies’ skin creates the potential for a number of skin problems.
Despite this, there remains a dearth of good quality evidence to inform practice. Published studies comparing
water with a skin-cleansing product have not provided adequate data to inform an adequately powered trial. Nor
have they distinguished between babies with and without a predisposition to atopic eczema. We conducted a
pilot study as a prequel to designing an optimum trial to investigate whether bathing with a specific cleansing
product is superior to bathing with water alone. The aims were to produce baseline data which would inform
decisions for the main trial design (i.e. population, primary outcome, sample size calculation) and to optimize the
robustness of trial processes within the study setting.
Methods: 100 healthy, full term neonates aged <24 hours were randomly assigned to bathing with water and
cotton wool (W) or with a cleaning product (CP). A minimum of bathing 3 times per week was advocated. Groups
were stratified according to family history of atopic eczema. Transepidermal water loss (TEWL), stratum corneum
hydration and skin surface pH were measured within 24 hours of birth and at 4 and 8 weeks post birth.
Measurements were taken on the thigh, forearm and abdomen. Women also completed questionnaires and diaries
to record bathing practices and medical treatments.
Results: Forty nine babies were randomized to cleansing product, 51 to water. The 95% confidence intervals (CI)
for the average TEWL measurement at each time point were: whole sample at baseline: 10.8 g/m2/h to 11.7 g/m2/
h; CP group 4 weeks: 10.9 g/m2/h to 13.3 g/m2/h; 8 weeks: 11.4 g/m2/h to 12.9 g/m2/h; W group 4 weeks:10.9 g/
m2/h to 12.2 g/m2/h; 8 weeks: 11.4 g/m2/h to 12.9 g/m2/h.
Conclusion: This pilot study provided valuable baseline data and important information on trial processes. The
decision to proceed with a superiority trial, for example, was inconsistent with our data; therefore a non-inferiority
trial is recommended.
Trial registrationISRCTN72285670
Background
The main role of the baby’s skin is to provide a barrier
which prevents infection, the loss of water from the
body, and penetration of irritants and allergens. These
functions depend on the maintenance of skin integrity
and pH balance. Babies are born with a pH of 6.4 which
reduces over three to four days to around 4.9 [1]. A
baby’s skin has a less developed epidermal barrier than
adults and thus is more prone to damage; recent
research suggests that the stratum corneum of infants
becomes ‘adult-like’ only after one year of life [2]. The
immaturity of babies’ skin creates the potential for a
number of skin problems, including atopic eczema,
infant Candida, cradle cap, baby acne and napkin der-
matitis [3]. These problems emphasize the importance
of appropriate skin cleansing routines.
The guidelines, ‘Routine postnatal care for women and
their babies’ [4], in the UK, recommend that cleansing
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agents added to bathwater should be avoided in the early
postnatal period. In contrast, The American Association
of Women’s Health, Obstetrics and Neonatal Nursing
(AWHONN) [5] produced clinical guidelines that recom-
mend the use of warm tap water for routine bathing with
the option to use mild cleansers that have a neutral pH
(5.5-7.0). However, there is a lack of evidence on which
to inform practice for the term newborn baby. A survey
of maternity units in the North West of England [6]
reported that a wide range of products were used by
women. Moreover, a systematic review of skin care
regimes, in the well term newborn, revealed no prospec-
tive trials that met the authors’ inclusion criteria [7]. As
such, there are no UK evidence-based guidelines about
neonatal skin care [8].
The Royal College of Midwives [9] called for further
research in this area. A recent European round-table of
Dermatologists also acknowledged the dearth of evi-
dence for skin care provision within 6 weeks of birth
[10]. The absence of randomized controlled trials com-
paring different skin cleansing routines is an important
issue because of the readiness to use wash products
among mothers [11].
Water is the basic component of any cleansing
routine. In many countries, despite the lack of strong
evidence in one direction or the other, water alone has
been considered the least harmful of all alternatives [4].
However, water may not be the optimal skin cleanser
for newborns. The buffering capacity of water is being
questioned, as it might increase skin pH; after washing
with water the skin surface pH may rise from 5.5 to 7.5.
This brings the pH to a level that maximizes the activity
of the skin proteases and therefore enhances skin barrier
breakdown [12]. The other problem with water alone is
that it is a poor cleanser as it does not remove fat-solu-
ble substances such as feces and sebum [13]. On the
extreme, over-exposure to water leads to higher trans-
epidermal water loss (TEWL) and a weakened skin bar-
rier [12]. An appropriately formulated cleansing product
may reduce these potential problems but would need to
be carefully evaluated.
Prior to the commencement of our study (in 2008),
we identified only two small trials that compared baby
bathing with a cleansing product to water. Both were
available in abstract form only, so our assessment of
methodology and interpretation of findings was necessa-
rily limited [14,15]. Following a small-scale study invol-
ving 57 infants, Garcia Bartels’ conclusion was that skin
barrier development of term newborns was not
adversely effected by bathing with a mild detergent
cleansing product. Galzote [14], using a different wash
product to Bartels [15], found that skin dryness was
reported more often in the ‘water only’ arm. These trials
were not large enough to provide definitive guidance.
One concern during skin care is atopic eczema. This
is a disease that arises as a result of the interaction of
environmental factors (such as harsh soap & detergents)
with variants in several genes [16,17]. Atopic eczema
starts as a weakness of the skin barrier [16-22]. This
breaks down allowing allergens to penetrate the skin
and interact with the immune system. Some of the
damage is caused by enzymes in the skin; proteases.
Proteases are pH sensitive enzymes with optimal activity
at 7.5 to 8.0 [20,21]. Harsh soap and detergent raise the
pH of the skin to within this range thereby increasing
the protease activity in the skin and potentially leading
to severe skin barrier breakdown. Washing with a deter-
gent which can damage and break down the skin barrier
may lead to an atopic flare in susceptible infants. This
may be important in bathing practices for newborn
babies, but this possibility has not been accounted for in
previous work.
As there was limited previous research in this area
and the available studies did not report key details of
methodology, careful preparation was required for an
adequately powered investigation. We therefore con-
ducted a qualitative, exploratory study [11] to gauge
support for a trial of bathing practices for term newborn
babies, in the UK. The results highlighted the inconsis-
tencies in information provided to parents and in cur-
rent newborn bathing practices. It also demonstrated
that health professionals and parents were likely to sup-
port a trial.
Therefore, we conducted a pilot randomized con-
trolled trial to compare a skin cleansing agent (specifi-
cally formulated for use on newborn skin), to water. We
hypothesized that an optimally formulated infant skin-
cleansing product improves skin barrier function (mea-
sured by TEWL) in newborn babies when compared
with bathing with water and cotton wool.
The pilot was designed to address the following uncer-
tainties in the design of the full study: the practicability
of using TEWL on newborn babies; the best outcome to
use (TEWL, pH or hydrometer), the best locations to
use (arm, leg or abdomen), the optimal time point for
measurement of the primary outcome and the value of
key parameters in the sample size calculation (the mag-
nitude of difference that would be important to detect
between the two groups and the precision of our
measurements).
Methods
Study site and Population
A randomized study was conducted from November
2008 to November 2009 in a teaching hospital in the
North West of England, where more than 8000 babies
are born annually. Babies were included if they were
born at 37 weeks gestation or more and were in good
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general health (determined by the investigator).
Excluded babies were those admitted to the neonatal
unit; having phototherapy; limb defects; non-traumatic
impairment of epidermal integrity or evidence of skin
disorder at first visit. For the purposes of this study, the
following normal variations were not considered skin
disorders; erythema neonatorum, erythema toxicum and
milia. Babies were also excluded if participating in
another clinical trial.
We set out to recruit a sample of babies with a family
history of atopic eczema (n = 30) and a sample of babies
who did not (n = 50). We believed that any effects were
likely to be more pronounced in infants with a family
history of atopic eczema and therefore we accounted for
this in the design of the trial. These numbers were
deemed to be sufficient to explore the nature and sizes
of differences in outcomes and to estimate the standard
deviations for each population.
The trial was approved by the Cheshire Research
Ethics Committee (09/H1017/3).
Recruitment and randomization
All potentially eligible women were supplied with study
information in the antenatal period and given time to
consider participating. Willing participants were invited
to complete a self administered questionnaire; this
enabled us to screen for those with and without a family
history of atopic eczema. The definition of “family his-
tory of atopic eczema” was “at least one of father,
mother, or sibling, who has had a medical-diagnosis of
atopic eczema and who has had topical steroid treat-
ment”. We considered this to be the simplest way of
identifying babies with a predisposition for atopic
eczema.
In the postnatal period a research midwife approached
women who had completed the questionnaire and
requested consent for their baby to participate in the
trial. Consenting women were randomized to the experi-
mental or control arm within 24 hours of giving birth
and prior to their baby being given his/her first bath.
Randomization was stratified according to whether or
not the baby fulfilled the definition of a family history of
atopic eczema. Blocked randomization was by sequen-
tially numbered sealed opaque envelopes held in the
Trust R&D Department. The randomization sequence
was computer generated.
Intervention
Babies were randomized to be bathed in water only or
bathed with the baby wash product. The wash product
was the commercially available Johnson’s® baby top- to-
toe™ wash (Johnson & Johnson Consumer Companies,
Inc.). This wash is a soap-free liquid cleanser specifically
designed for newborns’ skin. It is sodium lauryl sulphate
free and consists of a proprietary blend of non-ionic and
amphoteric surfactants that, when combined, result in
large, gentle cleansing micelles. The formula contains
only strictly necessary levels of well-tolerated preserva-
tives and a very low level of fragrance; it is pH adjusted
(around 5.5) and hypoallergenic. The INCI list com-
prised Aqua, Coco-Glucoside, Cocamidopropyl Betaine,
Citric Acid, Acrylates/C10-30 Alkyl Acrylate Crosspoly-
mer, Sodium Chloride, Glyceril Oleate, p-Anisic Acid,
Sodium Hydroxide, Phenoxyethanol, Sodium Benzoate,
Parfum.
All participating mothers were given a demonstration
bath by a Health Care assistant who had been instructed
on the appropriate advice. For those allocated to the
water only (control) arm, parents were not provided
with any products and were advised to bathe their baby
with water and cotton wool only. For those allocated to
the wash product (experimental) arm, parents were pro-
vided with sufficient baby wash and advised to use the
product as per instructions.
All participating parents were supplied with written
guidance on baby bathing. These instructions included
guidance on regularity of bathing and the non use of
other products, e.g. oils, sponges, flannels and baby
wipes. Participating women were requested to bathe
their baby a minimum of 3 times per week. The number
of times babies were bathed was recorded by the
women. They were also instructed to avoid any rubbing
of the baby’s skin and requested not to use any addi-
tional products.
Assessment of trial outcomes
All measurements were taken by researchers who were
unaware of treatment allocation. Measures were repeated
to check for intra-rater reliability. At the outset we had
intended to conduct all assessments in a controlled envir-
onment within the hospital setting. All baseline assess-
ments were conducted in the hospital. The remaining
follow-up assessments were also to be carried out in the
hospital. However 2 months into the study it became
clear that loss to follow-up was greater than expected. Of
the 31 women who agreed to participate during this per-
iod, 18 (58%) failed to attend their scheduled follow-up
appointments at 4 and 8 weeks. This was despite being
offered transport to attend and reimbursement for their
time and inconvenience. Women verbalized that attend-
ing the hospital was more disruptive than they had antici-
pated. As a consequence, and following discussion with
the Data Monitoring Committee and the manufacturers
of the assessment instruments, we decided to conduct
future assessments in the home.
Transepidermal Water Loss (TEWL)
A closed chamber TEWL instrument was used to mea-
sure the flux of water vapour evaporating from the skin
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surface (AquaFlux Model AF200). The measurements
were done by the same midwife at each time point for
the same participant. The midwife was formally trained
in obtaining such measurements, which were in accord
with published guidelines for TEWL measurements [23].
Measurements were made twice at each of three sites. A
baseline assessment was made prior to maternal transfer
into the community and before first bath. A second
assessment was made at 4 weeks and 8 weeks post
birth. Measurements were taken on the upper abdomen
(above nappy area), upper leg and forearm. The exact
locations where measurements were performed were
similar on all babies. This was achieved by measuring
from anatomical markers such as skin crease of the
wrist to midpoint on the volar forearm.
Skin surface pH and hydration were measured at the
same times and at the same sites as the TEWL measure-
ments using a pH meter (Courage and Khazaka skin pH
meter 900) and corneometer (Courage and Khazaka
Corneometer CM 820).
Clinical observations
The skin was observed and recorded by the assessing
midwife, at 4 and 8 weeks post birth using a validated
rating scale which records erythema, dryness, scaling
and need for medical products/attention [24]. Any skin
treatments were recorded by the mother.
Analysis
Data were input onto SPSS (Version 17) and double
entered to ensure accuracy. In accordance with recom-
mendations for pilot studies [25] data were summarized
for the whole study group and tabulated according to
allocation.
Individual experiences of women and members of the
research team were recorded throughout the study to
refine the study procedures for the main trial.
Results
Of 225 mothers who were approached to participate,
100 accepted. Figure 1 illustrates study recruitment, par-
ticipant follow-up and reasons for declining. We did,
however, conduct a post-hoc analysis according to
assessment location. For all measures, we found no clear
evidence of differences in reliability between locations
on baby (arm/leg/abdomen) or place of assessment
(home versus hospital). Reliability was good during hos-
pital measurements and was maintained when we con-
ducted follow-up assessments in the home. This was
crucial to the success of the pilot, as our original plan to
conduct all assessments in the hospital was unacceptable
to women. The reliability of the tests was good. At all
times and body locations the intra-class correlation of
repeated measurements was at least 0.92, with an aver-
age difference of approximately 0.35, and most
differences less than 2.0. Furthermore, the assessing
midwife observed that babies being assessed at home
were calmer than those in the hospital. Given the sensi-
tivity of the TEWL instrument, it is therefore likely that
more accurate readings were recorded as individual
assessments were easier to take and position of repeat
assessments was easier to locate. Figure 1 shows the
number of assessments at home and in the hospital.
Table 1 illustrates the baseline details for the babies
who participated. As shown, 27 participants had a family
history of atopic eczema.
An important reason for conducting the pilot was to
determine compliance, in terms of the allocated trial
arm and adherence to the bathing guidance. Compliance
was shown to be an issue. Women’s diaries and verbal
reports indicated that between 3 and 4 weeks post birth,
mothers perceived their baby’s skin to be becoming dry.
Although we requested that women refrain from using
additional products on their babies’ skin, this was the
time in which they were most likely to introduce pro-
ducts into bathing regimes. As a consequence, there
were 53 babies using products at the time when our pri-
mary outcome measure was being assessed; this was
similar in each treatment group and despite the fact
that women remained committed to completing the
study. The number using products may in fact be an
underestimate as some women may not have revealed
the protocol violation. Women appeared to comply with
the minimum bathing occasions of three; the median
number of bathing occasions per week were 3 (range
2-7) for both groups.
As can be seen from table 2, there is no consistent evi-
dence of numerical differences or trends in the data,
between the trials arms, in either direction. This is true
within all assessments (TEWL, hydration and skin surface
pH) and location of assessments. Similarly, there is no
evidence of difference between those babies with a family
history of atopic eczema and those without. We calcu-
lated the 95% confidence intervals (CI) for the average
TEWL measurement at each time point. At baseline the
CI for the entire sample (n = 100) was 10.8 g/m2/h to
11.7 g/m2/h; after intervention at 4 weeks it was 10.9 g/
m2/h to 13.3 g/m2/h (product) and 10.9 g/m2/h to 12.2
g/m2/h (Water); at 8 weeks it was 11.4 g/m2/h to 12.9 g/
m2/h (product) and 11.4 g/m2/h to 12.9 g/m2/h (Water).
The midwife assessed the babies’ skin, according to a
rating scale [24] at 4 and 8 weeks post birth. The rating
scale contained three observations; dryness, erythema
and breakdown/excoriation. Each observation was
scored separately; a score of 1 indicated no evidence of
abnormal skin whilst a score of 3 indicated some sever-
ity. None of the babies in the study scored 3, when
assessed. As can be seen in table 3, few babies scored 2.
The remainder of babies scored 1.
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Discussion
The primary purpose of conducting this pilot trial was
to inform a robust definitive trial of water and cotton
wool versus a mild wash product for newborn babies.
We present one of the largest baseline datasets on
newborn skin assessments to date; information which
is pivotal to the design of future studies in this field.
However, when we set out to design the trial there was
little published information on methodology or data
from studies on newborns to assist in trial design.
Although it is important to report what works in a
study (as is usual in reports of a main trial), it is also
important to share what does not work. There are
many ways to design this type of trial and the field will
only advance if the processes of trial design are shared
transparently. In doing this, we reveal a number of
important process issues, that would not normally be
available to readers.
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Figure 1 Pilot study recruitment flow chart.
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In our qualitative study [11], we asked women to indi-
cate what they thought would be the optimum time to
be approached about participating in this trial. Views
were mixed; some suggested that the antenatal period
was best, while others recommended the postnatal per-
iod. In this pilot study we decided to give women infor-
mation in the antenatal period and re approach them in
the postnatal period. The reality was that the majority
of women had not absorbed the information prior to
giving birth and/or was not ready to make a decision
until the baby was born. It was only after giving birth to
a healthy baby, and being faced with a real decision,
that, for most women, the information was internalized
and informed consent could be obtained. Although
postnatal consent is appropriate, no woman objected to
being given the information in the antenatal period,
therefore the approach adopted was acceptable.
We conducted our pilot trial based on a superiority
hypothesis. However, although the study was not
designed to carry out a hypothesis test, examination of
the data suggested that the hypothesis was not plausible.
There was no convincing trend for superiority for any
measurements on any part of the body. Furthermore,
there was no clear evidence of any differences in any
Table 1 Participant Baseline details
No family history of
atopic eczema
N = 73
Family history of
atopic eczema
N = 27
Water Wash Water Wash
N = 37 N = 36 N = 14 N = 13
Sex of baby
Male 15 17 6 5
Female 22 19 8 8
Mums Ethnicity
White British 33 28 14 12
Black Minority Ethnic 0 4 0 0
Mixed Race 2 2 0 0
Other 2 0 0 0
Missing 0 2 0 1
Baby’s Ethnicity
White British 30 29 13 10
Black Minority Ethnic 0 2 0 0
Mixed Race 4 1 0 1
Other 1 0 0 0
Missing 2 4 1 2
Feeding method
Breast 14 12 7 5
Bottle 21 21 7 8
Combined 2 3 0 0
Parity
Primiparous 14 18 5 2
Multiparous 23 19 9 11
Gestational age at
birth
(days, mean (SD)) 282.9
(6.3)
281.9
(7.3)
283.6
(7.2)
278.4
(6.7)
Mode of birth
Caesarean section 0 0 0 0
Normal vaginal 33 34 14 13
Instrumental 4 2 0 0
Maternal age mean (SD) 26.4 (5.2) 27.2 (5.6) 29.2 (5.0) 29.8 (5.3)
Table 2 Skin Functional Parameters/assessments
No family history of
atopic eczema
N = 73
Family history of
atopic eczema
N = 27
Water Wash Water Wash
N = 37 N = 36 N = 14 N = 13
TEWL (g/m2/h)
<24 hours
Arm 12.7 (3.0) 12.2 (2.6) 11.8 (2.3) 11.8 (2.4)
Leg 12.0 (2.8) 11.1 (1.8) 10.9 (1.6) 11.5 (2.6)
Abdomen 10.4 (2.9) 10.4 (2.5) 9.6 (2.1) 9.2 (2.0)
4 weeks post birth Arm 12.1 (2.7) 12.6 (3.7) 12.1 (2.7) 12.8 (2.9)
Leg 12.2 (1.6) 12.5 (3.7) 12.2 (1.6) 14.3 (4.1)
Abdomen 10.1 (2.1) 10.7 (3.8) 10.1 (2.1) 11.2 (2.5)
8 weeks post birth
Arm 11.1 (2.1) 12.5 (2.8) 11.1 (2.1) 13.1 (3.9)
Leg 11.9 (2.1) 12.6 (2.3) 11.9 (2.1) 12.7 (3.2)
Abdomen 11.9 (3.2) 11.3 (2.4) 11.9 (3.2) 11.4 (1.9)
Hydrometer
(AU)<24 hours
Arm 36.1 (8.2) 32.8 (7.8) 40.7 (10.7) 36.6 (11.8)
Leg 35.0 (9.8) 31.0 (7.2) 35.0 (10.0) 36.6 (9.8)
Abdomen 41.1 (13.6) 37.7 (8.4) 41.8 (9.7) 42.0 (8.3)
4 weeks post birth
Arm 68.1 (11.3) 66.5 (13.3) 64.9 (14.7) 64.2 (13.9)
Leg 58.1 (14.5) 57.7 (11.3) 57.7 (13.7) 59.0 (13.2)
Abdomen 75.0 (10.7) 74.5 (9.4) 73.7 (16.4) 71.3 (11.6)
8 weeks post birth
Arm 74.4 (12.8) 74.4 (11.2) 72.1 (13.0) 68.6 (15.9)
Leg 68.1 (12.0) 65.9 (13.8) 63.8 (9.4) 61.4 (16.0)
Abdomen 65.2 (12.4) 70.0 (10.9) 69.5 (13.1) 67.6 (10.4)
Skin Ph <24 hours
Arm 6.89 (0.58) 6.76 (0.53) 6.63 (0.74) 6.71 (0.88)
Leg 6.91 (0.78) 6.69 (0.59) 6.44 (0.66) 6.58 (0.67)
Abdomen 6.90 (0.60) 6.63 (0.56) 6.76 (0.62) 6.80 (0.85)
4 weeks post birth
Arm 5.06 (0.43) 5.17 (0.37) 5.01 (0.52) 5.19 (0.28)
Leg 5.14 (0.38) 5.31 (0.45) 5.07 (0.43) 5.20 (0.50)
Abdomen 5.29 (0.38) 5.30 (0.35) 4.92 (0.51) 5.47 (0.44)
8 weeks post birth
Arm 5.14 (0.36) 5.12 (0.32) 5.13 (0.31) 5.09 (0.30)
Leg 5.11 (0.34) 5.27 (0.58) 5.01 (0.37) 5.24 (0.52)
Abdomen 5.27 (0.38) 5.40 (0.51) 5.05 (0.33) 5.27 (0.68)
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direction. The size of any of the small differences
observed was deemed of little clinical importance by the
Trial Steering Committee and Data Monitoring Com-
mittee. Therefore, a trial designed on the principles of
non-inferiority appears most appropriate. The trial
design therefore should be to generate data concerning
the hypothesis that this mild skin cleansing product is
not inferior to bathing with water only in its effect on
skin barrier function. Moreover, as there was no differ-
ence between body parts, it seems reasonable, in future
trials, to analyze an average assessment score.
There was no evidence of consistent differences
between those babies with and without a family history
of atopic eczema. If those with a family history of atopic
eczema had shown more evidence of barrier dysfunc-
tion, this may have led us to design a trial based on this
population only. Such a trial would be attractive because
if a trial recruited a group with a propensity to disease
and found no difference between treatments it would be
unlikely that we would find a difference in a ‘healthy’
population. Given our results, however, it appears
appropriate to include both groups, with stratification
for family history. On a practical level this is more feasi-
ble, as those with a family history of atopic eczema were
particularly difficult to recruit.
The importance of assessing compliance was highlighted
in this pilot. Although women in our qualitative study [11]
and at recruitment for this pilot study told us that they
were happy to conform to protocol, compliance was an
issue, making the findings difficult to interpret. This is one
possible explanation for not observing a treatment differ-
ence. Some women, particularly those having their first
baby, may not have been able to anticipate the difficulties
of daily routines with a newborn baby. Given that parents
introduced products around 3-4 weeks, and it is impossi-
ble to enforce or ensure compliance, it is more appropriate
to have a primary endpoint prior to this.
This study provides an important exemplar of the
importance of conducting a pilot study, particularly
when there is a dearth of prior knowledge. The findings
have indicated that the research processes, trial manage-
ment and chosen primary outcome (i.e. TEWL) were
appropriate. The feasibility of the main trial was also
established. The trial management group and the inde-
pendent Data Monitoring Committee have reviewed the
process and data. A small number of important amend-
ments to the trial have been made as a result of the
findings of the pilot study. Our experience illustrates
some contrasts between our qualitative study about the
issues involved in a potential trial and what actually
happened. For example the timing of information-giving
was refined from the suggestions arising from the quali-
tative study. This provides an instructive example of the
need to develop a large trial in several stages.
Three relevant RCT’s, two by the same authors, were
published after the completion of our pilot trial. Bartels
study [26] tested the hypothesis that neither twice-
weekly washing nor bathing would harm the natural
adaptation of the skin barrier with respect to long-term
effects on skin function in healthy newborns. The
bathed group showed statistically significant lower
TEWL on the buttock and higher hydration on abdo-
men and forehead compared to the wash group at day
28. The authors claim that both skin care regimes do
not harm the adaptation of the skin barrier in healthy
newborns in the first 24 hours of life. The second study
[27], aimed to test the hypothesis that twice-weekly
bathing with a commercially available baby wash gel and
additional baby cream would not harm the natural adap-
tation of skin barrier in healthy newborns. At 8 weeks,
the group using clear water and topical cream had lower
TEWL measurements on their fronts, abdomen and
upper legs as well as higher stratum corneum hydration
on their fronts and abdomen compared with bathing
Table 3 Clinical skin assessment
No family history of atopic eczema
N = 73
Family history of atopic eczema
N = 27
Skin assessment scale (recorded by midwife) Water
N = 37
Wash
N = 36
Water
N = 14
Wash
N = 13
Baseline
Dryness (2 - Dry skin, visible flaking) 4 (4%) 6 (6%) 3 (3%) 3 (3%)
4 weeks
Dryness (2 - Dry skin, visible flaking) 3 (4%) 5 (7%) 1 (1%) 1 (1%)
Erythema (2 - Visible erythema <50% of body surface) 3 (4%) 3 (4%) 2 (3%) 2 (3%)
8 weeks
Dryness (2 - Dry skin, visible flaking) 1 (1%) 0 1 (1%) 0
Erythema (2 - Visible erythema <50% of body surface) 3 (4%) 6 (8%) 3 (4%) 2 (3%)
Need for skin treatment 1* 2* 0 0
* Health professional prescribed aqueous cream
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with water only. The group bathing in wash gel had
lower pH on all sites compared with bathing in water
only at week 8. No differences in sebum levels, micro-
biological colonization and skin scores were found. The
authors conclude that skin adaption as a barrier func-
tion was not harmed by tested skincare regimens in full
term healthy infants. The final RCT [28] was a three
armed trial, conducted in the Philippines, which com-
pared a Johnson’s® baby top- to-toe™ wash (Johnson &
Johnson Consumer Companies, Inc.) with Sebamed®
baby liquid cleanser and water alone; 60 babies were
randomized in each arm. Assessment measures were
similar to those reported in the Garcia Bartels studies,
with the addition of skin oxyhemoglobin, deoxyhemo-
globin and parental satisfaction measures. The authors
conclude that all three regimes are ‘safe for use in
infants with normal skin.’ However, although these three
studies provide novel information relating to term baby
bathing none report a priori primary outcomes or sam-
ple sizes, which make it difficult to assess the extent to
which the results could have arisen by chance. Further-
more, it is not clear how the results of either trial relate
to clinically important safety outcomes since the investi-
gators do not state what they mean by “harm”. None of
these published studies use home measurements. In
our experience the families who complete a trial using
hospital assessments are a subset of families who were
committed to the study. This subset may not be repre-
sentative. Such a committed group may be particularly
concerned about skin and skin care. This concern may
mean that their skin care practices at home may be
different from other families. We have described and
validated an approach that reduces the potential for
selection bias.
Conclusion
Our study adds to existing literature by providing valu-
able baseline data and important information on trial
processes. Our study observations were consistent with
previously published papers but we believe that the way
forward is to test the hypothesis in a properly designed
and adequately powered non-inferiority trial.
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